Axendia’s 2024 Life Sciences Industry Radar Axendia unveiled its fifth annual Life Science Industry Radar on February 15, 2024, during a live “Straight from the Source” […]
Plotting a Course to Success in the Age of Price Negotiations Read More »
The FDA has taken another step towards realizing their vision for encouraging pharmaceutical quality management practices. FDA’s Center for Drug Evaluation and Research (CDER) has developed
FDA Encourages Industry to Achieve Quality Management Maturity (QMM) Read More »
FDA’s Center for Drug Evaluation and Research (CDER) recently released its fifth annual report on the State of Pharmaceutical Quality. It reviews the state of
FDA Reports on the State of Pharmaceutical Quality Read More »
The Inflation Reduction Act (IRA) will drive a significant change in the pharmaceutical industry, empowering Medicare to negotiate the prices of high-cost single-source brand-name drugs
Price Negotiations: 10 Initiatives Pharma Must Consider To Mitigate Impacts Read More »
An Axendia “Straight from the Source” Event Axendia revealed its 2023 Life Sciences Radar on February 2, 2023, during a live event. Members of our
Life Science Industry Predictions for 2023 and Beyond! Read More »
